ReviewMediastinum (Hong Kong, China)2026
Reframing thymic epithelial tumors through single-cell transcriptomics: a narrative review.
Review in Mediastinum (Hong Kong, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Thymic epithelial tumors (TETs) are rare neoplasms originating from thymic epithelial cells (TECs). They exhibit histological, molecular, and immunological diversity shaped by aberrant interactions between neoplastic TECs and immune cells. World Health Organization (WHO) histological classification effectively captures their clinicopathological features, whereas inter- and intra-subtype heterogeneity persists. In this point, single-cell transcriptomics is well-suited to resolve cellular heterogeneity in TETs. This narrative review synthesizes findings from recent single-cell studies that illuminate epithelial subpopulations, intra-tumoral immune landscape, and disease-specific aberrations such as myasthenia gravis (MG)-associated phenotypes in TETs. Methods: We conducted a focused narrative review on three key studies that applied single-cell RNA sequencing (scRNA-seq) to primary human TETs. Key Content and Findings: Single-cell analyses identified a distinct TEC subpopulation ectopically expressing neuromuscular antigens, termed neuromuscular medullary TECs (nmTECs), in MG-associated thymomas, implicating aberrant antigen presentation and immune cell recruitment in autoantibody production. Other studies delineated tumor epithelial programs that shape the immune microenvironment, linking TEC transcriptional identities to the persistence of immature T-cells or dominance of mature T-cells. Bioinformatic approaches of ligand-receptor networks supported pathogenic crosstalk between neoplastic TECs and immune cells. Notably, independent groups converged on functionally oriented classifications that align across studies, stratifying TETs by epithelial lineage programs and immune composition with correspondence to biological behavior and prognosis. Conclusions: Single-cell approaches have revealed TET heterogeneity encompassing abnormal epithelial cell states, immune development trajectories, and autoimmune-associated molecular programs with high resolution. The ongoing accumulation of single-cell transcriptomics datasets would refine a cell-centric framework for TET classification and pathogenesis, while also deepening insight into normal TEC biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.